Acceleron And Celgene Expand Anemia Collaboration With Second Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.